


What is Claimed is:

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt form thereof, wherein

R¹ is selected from methyl; and

R² is selected from H, methyl, and ethyl.

2. A compound of claims 1, wherein

R² is H.

3. A compound of claims 1, wherein

R² is methyl.

4. A compound of claims 1, wherein

R² is ethyl.

5. A compound of claim 1 or a pharmaceutically acceptable salt, wherein the compound is selected from:

N-[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]-N'-
 {(1R,2S)-3-[(3S)-3-(4-fluorobenzyl)-1-piperidinyl]-2-hydroxy-1-methylpropyl}urea;

N-{(1R,2S)-3-[(3S)-3-(4-fluorobenzyl)-1-piperidinyl]-2-hydroxy-1-methylpropyl}-N'-[3-(1-methyl-1H-tetraazol-5-yl)phenyl]urea; and

5 N-{(1R,2S)-3-[(3S)-3-(4-fluorobenzyl)-1-piperidinyl]-2-hydroxy-1-methylpropyl}-N'-[3-methyl-5-(1-methyl-1H-tetraazol-5-yl)phenyl]urea.

6. A pharmaceutical composition comprising a
10 pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

7. A method for modulation of chemokine receptor
15 activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 1.

8. A method for treating asthma, comprising
20 administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 1.

9. The method of claim 7 wherein modulation of
25 chemokine receptor activity comprises contacting a CCR3 receptor with an effective inhibitory amount of the compound.

10. A method for treating inflammatory disorders
30 comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

11. A method for treating disorders, wherein the
35 disorder is selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic

pulmonary fibrosis, bullous pemphigoid, helminthic
parasitic infections, allergic colitis, eczema,
conjunctivitis, transplantation, familial eosinophilia,
eosinophilic cellulitis, eosinophilic pneumonias,
5 eosinophilic fasciitis, eosinophilic gastroenteritis, drug
induced eosinophilia, HIV infection, cystic fibrosis,
Churg-Strauss syndrome, lymphoma, Hodgkin's disease, and
colonic carcinoma.

10 12. The method according to Claim 11, wherein the
disorder is selected from asthma, allergic rhinitis, atopic
dermatitis, and inflammatory bowel diseases.

 13. The method according to Claim 12, wherein the
15 disorder is asthma.